Navidea Biopharmaceuticals Inc (NAVB)

[XJINVESTOR]

The best thing about it is they avoid bankruptcy and get rid of an extremely hostile CRG lender. This also saves them 6.7 million a year just in interest payments they won't have to pay.

On top of it all, they really could not move forward with this hanging over their head. They can now get going on their drug pipeline and concentrate on Lymphoseek sales both in North America and abroad.

There are many shorts that will need to cover. Right before close the price jumped from .93 to .95 from a huge short cover. Look for more of that in the coming weeks. But most of all -- look for news on the European sales of Lymphoseek which should come at any time. But make no mistake - before they could move forward, this deal had to get done.